These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3495987)

  • 21. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia.
    Jehn U; Göldel N; Rienmüller R; Wilmanns W
    Med Oncol Tumor Pharmacother; 1988; 5(1):41-7. PubMed ID: 3367672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
    Zittoun R; Rio B; Marie JP; Blanc CM
    Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive treatment of acute leukemia in adults 70 years of age and older.
    Walters RS; Kantarjian HM; Keating MJ; Estey EH; McCredie KB; Freireich EJ
    Cancer; 1987 Jul; 60(2):149-55. PubMed ID: 3474052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
    Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
    Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
    Peters WG; Willemze R; Colly LP
    Scand J Haematol Suppl; 1986; 44():7-16. PubMed ID: 3515513
    [No Abstract]   [Full Text] [Related]  

  • 27. Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.
    Esumi N; Todo S; Arakawa S; Imashuku S
    J Clin Oncol; 1986 Jul; 4(7):1089-93. PubMed ID: 3459812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
    Maschmeyer G; Hiddemann W; Kreutzmann H; Wendt F
    Onkologie; 1987 Feb; 10(1):18-21. PubMed ID: 3295621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
    Kumagawa M; Suzuki K; Nagano M; Takamatsu Y; Suzumiya J; Tamura K
    Rinsho Ketsueki; 2003 Jun; 44(6):404-6. PubMed ID: 12884821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Low-dose oral etoposide and subcutaneous injection of low-dose cytosine arabinoside (Et-A non i.v.) with or without minimum anthracycline for refractory acute non-lymphoblastic leukemia].
    Tsukaguchi M; Furukawa Y; Kitani T
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1603-7. PubMed ID: 9725056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
    Dhaliwal HS; Shannon MS; Barnett MJ; Prentice HG; Bragman K; Malpas JS; Lister TA
    Cancer Chemother Pharmacol; 1986; 18(1):59-62. PubMed ID: 3463435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
    Daenen S; Löwenberg B; Sonneveld P; van Putten WL; Verhoef G; Verdonck LF; van Veldhoven M; Huijgens PC
    Leukemia; 1994 Jan; 8(1):6-10. PubMed ID: 8289499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term high-dose treatment in bad-risk ALL and lymphoblastic NHL.
    Willemze R; Peters WG; Colly LP
    Br J Haematol; 1987 Apr; 65(4):501-2. PubMed ID: 3472590
    [No Abstract]   [Full Text] [Related]  

  • 35. Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia.
    Leone G; Pagano L; Marra R; Di Pietro N; Storti S; Sica S; D'Onofrio G; Ganzina F
    Haematologica; 1989; 74(1):57-61. PubMed ID: 2498185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
    Marit G; David B; Reiffers J; Broustet A
    Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
    Ghaddar HM; Plunkett W; Kantarjian HM; Pierce S; Freireich EJ; Keating MJ; Estey EH
    Leukemia; 1994 Aug; 8(8):1269-74. PubMed ID: 8057660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
    van Geel BM; Huijgens PC; Ossenkoppele GJ; Wijermans PW; Langenhuijsen MM
    Neth J Med; 1989 Oct; 35(3-4):128-36. PubMed ID: 2601790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.